N-(3-oxo-acyl) homoserine lactone inhibits tumor growth independent of Bcl-2 proteins

CORC > 合肥物质科学研究院 > 中国科学院合肥物质科学研究院 > 技术生物与农业工程研究所

	N-(3-oxo-acyl) homoserine lactone inhibits tumor growth independent of Bcl-2 proteins
	Zhao, Guoping 1,7; Neely, Aaron M.1; Schwarzer, Christian 4; Lu, Huayi 5; Whitt, Aaron G.1; Stivers, Nicole S.1; Burlison, Joseph A.2,3; White, Carl 6; Machen, Terry E.4; Li, Chi 1
刊名	ONCOTARGET
	2016-02-02
卷号	7 期号:5 页码:5924-5942
关键词	Homoserine Lactone Bcl-2 Bak Bax Tumor
文献子类	Article
英文摘要	Pseudomonas aeruginosa produces N-(3-oxododecanoyl)-homoserine lactone (C12) as a quorum-sensing molecule for bacterial communication. C12 has also been reported to induce apoptosis in various types of tumor cells. However, the detailed molecular mechanism of C12-triggerred tumor cell apoptosis is still unclear. In addition, it is completely unknown whether C12 possesses any potential therapeutic effects in vivo. Our data indicate that, unlike most apoptotic inducers, C12 evokes a novel form of apoptosis in tumor cells through inducing mitochondrial membrane permeabilization independent of both pro- and anti-apoptotic Bcl-2 proteins. Importantly, C12 inhibits tumor growth in animals regardless of either pro- or anti-apoptotic Bcl-2 proteins. Furthermore, opposite to conventional chemotherapeutics, C12 requires paraoxonase 2 (PON2) to exert its cytotoxicity on tumor cells in vitro and its inhibitory effects on tumor growth in vivo. Overall, our results demonstrate that C12 inhibits tumor growth independent of both pro- and anti-apoptotic Bcl-2 proteins, and through inducing unique apoptotic signaling mediated by PON2 in tumor cells.
WOS关键词	PSEUDOMONAS-AERUGINOSA ; CANCER-CELLS ; FAMILY PROTEINS ; TRIGGERS APOPTOSIS ; HUMAN PARAOXONASES ; OXIDATIVE STRESS ; CARCINOMA-CELLS ; SMALL-MOLECULE ; CYTOCHROME-C ; IN-VITRO
WOS研究方向	Oncology ; Cell Biology
语种	英语
WOS记录号	WOS:000369952800060
资助机构	National Institutes of Health(CA106599 ; National Institutes of Health(CA106599 ; National Institutes of Health(CA106599 ; National Institutes of Health(CA106599 ; National Institutes of Health(CA106599 ; National Institutes of Health(CA106599 ; National Institutes of Health(CA106599 ; National Institutes of Health(CA106599 ; University of Louisville Research Initiation Grant ; University of Louisville Research Initiation Grant ; University of Louisville Research Initiation Grant ; University of Louisville Research Initiation Grant ; University of Louisville Research Initiation Grant ; University of Louisville Research Initiation Grant ; University of Louisville Research Initiation Grant ; University of Louisville Research Initiation Grant ; Cystic Fibrosis Research, Inc. New Horizons ; Cystic Fibrosis Research, Inc. New Horizons ; Cystic Fibrosis Research, Inc. New Horizons ; Cystic Fibrosis Research, Inc. New Horizons ; Cystic Fibrosis Research, Inc. New Horizons ; Cystic Fibrosis Research, Inc. New Horizons ; Cystic Fibrosis Research, Inc. New Horizons ; Cystic Fibrosis Research, Inc. New Horizons ; CAS Pioneer Hundred Talents Program ; CAS Pioneer Hundred Talents Program ; CAS Pioneer Hundred Talents Program ; CAS Pioneer Hundred Talents Program ; CAS Pioneer Hundred Talents Program ; CAS Pioneer Hundred Talents Program ; CAS Pioneer Hundred Talents Program ; CAS Pioneer Hundred Talents Program ; National Natural Science Foundation of China(81300769) ; National Natural Science Foundation of China(81300769) ; National Natural Science Foundation of China(81300769) ; National Natural Science Foundation of China(81300769) ; National Natural Science Foundation of China(81300769) ; National Natural Science Foundation of China(81300769) ; National Natural Science Foundation of China(81300769) ; National Natural Science Foundation of China(81300769) ; CA175003 ; CA175003 ; CA175003 ; CA175003 ; CA175003 ; CA175003 ; CA175003 ; CA175003 ; GM106386 ; GM106386 ; GM106386 ; GM106386 ; GM106386 ; GM106386 ; GM106386 ; GM106386 ; RR018733 ; RR018733 ; RR018733 ; RR018733 ; RR018733 ; RR018733 ; RR018733 ; RR018733 ; PN2-EY-018241) ; PN2-EY-018241) ; PN2-EY-018241) ; PN2-EY-018241) ; PN2-EY-018241) ; PN2-EY-018241) ; PN2-EY-018241) ; PN2-EY-018241) ; National Institutes of Health(CA106599 ; National Institutes of Health(CA106599 ; National Institutes of Health(CA106599 ; National Institutes of Health(CA106599 ; National Institutes of Health(CA106599 ; National Institutes of Health(CA106599 ; National Institutes of Health(CA106599 ; National Institutes of Health(CA106599 ; University of Louisville Research Initiation Grant ; University of Louisville Research Initiation Grant ; University of Louisville Research Initiation Grant ; University of Louisville Research Initiation Grant ; University of Louisville Research Initiation Grant ; University of Louisville Research Initiation Grant ; University of Louisville Research Initiation Grant ; University of Louisville Research Initiation Grant ; Cystic Fibrosis Research, Inc. New Horizons ; Cystic Fibrosis Research, Inc. New Horizons ; Cystic Fibrosis Research, Inc. New Horizons ; Cystic Fibrosis Research, Inc. New Horizons ; Cystic Fibrosis Research, Inc. New Horizons ; Cystic Fibrosis Research, Inc. New Horizons ; Cystic Fibrosis Research, Inc. New Horizons ; Cystic Fibrosis Research, Inc. New Horizons ; CAS Pioneer Hundred Talents Program ; CAS Pioneer Hundred Talents Program ; CAS Pioneer Hundred Talents Program ; CAS Pioneer Hundred Talents Program ; CAS Pioneer Hundred Talents Program ; CAS Pioneer Hundred Talents Program ; CAS Pioneer Hundred Talents Program ; CAS Pioneer Hundred Talents Program ; National Natural Science Foundation of China(81300769) ; National Natural Science Foundation of China(81300769) ; National Natural Science Foundation of China(81300769) ; National Natural Science Foundation of China(81300769) ; National Natural Science Foundation of China(81300769) ; National Natural Science Foundation of China(81300769) ; National Natural Science Foundation of China(81300769) ; National Natural Science Foundation of China(81300769) ; CA175003 ; CA175003 ; CA175003 ; CA175003 ; CA175003 ; CA175003 ; CA175003 ; CA175003 ; GM106386 ; GM106386 ; GM106386 ; GM106386 ; GM106386 ; GM106386 ; GM106386 ; GM106386 ; RR018733 ; RR018733 ; RR018733 ; RR018733 ; RR018733 ; RR018733 ; RR018733 ; RR018733 ; PN2-EY-018241) ; PN2-EY-018241) ; PN2-EY-018241) ; PN2-EY-018241) ; PN2-EY-018241) ; PN2-EY-018241) ; PN2-EY-018241) ; PN2-EY-018241)
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/22293]
专题	合肥物质科学研究院_技术生物与农业工程研究所
作者单位	1.Univ Louisville, Mol Targets Program, Louisville, KY 40202 USA 2.Univ Louisville, James Graham Brown Canc Ctr, Struct Biol Program, Dept Med, Louisville, KY 40202 USA 3.Univ Louisville, James Graham Brown Canc Ctr, Struct Biol Program, Dept Pharmacol & Toxicol, Louisville, KY 40202 USA 4.Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA 5.Jilin Univ, Hosp 2, Changchun 130041, Jilin Province, Peoples R China 6.Rosalind Franklin Univ Med & Sci, Dept Physiol & Biophys, N Chicago, IL 60064 USA 7.Chinese Acad Sci, Hefei Inst Phys Sci, Inst Tech Biol & Agr Engn, Hefei 230031, Anhui, Peoples R China
推荐引用方式 GB/T 7714	Zhao, Guoping,Neely, Aaron M.,Schwarzer, Christian,et al. N-(3-oxo-acyl) homoserine lactone inhibits tumor growth independent of Bcl-2 proteins[J]. ONCOTARGET,2016,7(5):5924-5942.
APA	Zhao, Guoping.,Neely, Aaron M..,Schwarzer, Christian.,Lu, Huayi.,Whitt, Aaron G..,...&Li, Chi.(2016).N-(3-oxo-acyl) homoserine lactone inhibits tumor growth independent of Bcl-2 proteins.ONCOTARGET,7(5),5924-5942.
MLA	Zhao, Guoping,et al."N-(3-oxo-acyl) homoserine lactone inhibits tumor growth independent of Bcl-2 proteins".ONCOTARGET 7.5(2016):5924-5942.